Crott Ralph
1IRSS, Université Catholique de Louvain, Clos Chapelle aux Champs 30 bte 30.15, 1200, Brussels, Belgium.
Expert Rev Pharmacoecon Outcomes Res. 2014 Aug;14(4):569-76. doi: 10.1586/14737167.2014.908711. Epub 2014 Jun 7.
Over the last years several mapping or cross-walking algorithms for deriving utilities from QLQ-C30 scores have been published. However their external predictive accuracy has not yet been systematically compared.
We tested the external validity of previously published mapping algorithms to transform the European Organization for Research and Treatment of Cancer QLQ-C30 questionnaire responses to EQ-5D derived Utilities.
When applied to different data sets, the currently published mapping showed a large variation between algorithms of the values of the mapped utilities, a low accuracy of the mapping compared to the observed EQ-5D utilities and no consistent performance between competing algorithms.
Therefore direct mapping from QLQ-C30 profiles to EQ-5D utilities using published algorithms should be viewed cautiously.
在过去几年中,已经发表了几种用于从QLQ-C30评分中推导效用值的映射或交叉转换算法。然而,它们的外部预测准确性尚未得到系统比较。
我们测试了先前发表的映射算法的外部有效性,以将欧洲癌症研究与治疗组织的QLQ-C30问卷回答转换为EQ-5D推导的效用值。
当应用于不同数据集时,当前发表的映射显示,映射后的效用值算法之间存在很大差异,与观察到的EQ-5D效用值相比,映射准确性较低,并且竞争算法之间没有一致的性能表现。
因此,应谨慎看待使用已发表算法从QLQ-C30概况直接映射到EQ-5D效用值的方法。